Semaglutide eyesight loss from the drug side effect NAION is being investigated as possible drug injury lawsuits to be filed on behalf of patients against Novo Nordisk, the responsible drug company for Ozempic, Wegovy, and Rybelsus. The active ingredient for each of those three Novo Nordisk drugs is semaglutide.
There are a couple of recent medical studies about semaglutide being associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) that provide us with more information about this semaglutide eyesight loss drug side effect for Ozempic, Wegovy, and Rybelsus.
The first study was reported in the International Journal of Retina and Vitreous. It found that semaglutide was associated with a higher risk of NAION, having a 2.19 hazard ratio. The second study, which is in preprint form and not yet published in a peer-reviewed journal (but was posted December 11, 2024, online at medRxiv) “…confirms that use of semaglutide is associated to an increased risk of NAION but also that the excess absolute risk is low.”
People diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) often experience some degree of permanent vision impairment, which can be life-altering. The Brigham and Women’s Hospital website provides basic medical information about NAION.
Our last article concerning Semaglutide eyesight loss from the drug side effect NAION was “Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect“, posted in December 2024. An earlier article, “Ozempic Side Effects Include Eye Problems With Possible Vision Loss“, was posted in July 2024.
We are investigating drug injury lawsuits seeking legal compensation for people who have been diagnosed with semaglutide eyesight loss from the drug side effect NAION (non-arteritic anterior ischemic optic neuropathy) while using one of Novo Nordisk’s semaglutide drugs, Ozempic, Wegovy, or Rybelsus.
[Read the article in full at source]Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation